WE WANNA NEW DRUG
“One that won’t make me sick/ One that won’t make me crash my car/ and make me feel three feet thick…” Huey Lewis is singing about love, but he voices very human concerns when it comes to the medicines that heal bodies and minds.
Last week, the WEEKLY explored how researchers identify drug targets—the molecules in our bodies that make good candidates for therapeutic action. It’s a painstaking but strategic process, and only the first step toward Huey’s mythical remedy.
There are small molecule drugs and large molecule drugs. Small molecule drugs include medicines most of us know, such as aspirin and over-the-counter cold remedies. In contrast, large molecule drugs, also known as biologics, are often specialty drugs, delivered through injection by a healthcare professional.
Therapeutic choice hinges on a disease’s origins. If an illness originates outside the cell, a biologic is a logical choice since it is too big to enter the cell. Though more expensive to produce, biologics typically cause fewer adverse reactions than their smaller counterparts.
Small molecule drugs attack disease from within the cell. The downside? Their small size means they have the potential to also activate many off-target molecules. This collateral damage increases the chance of adverse reactions.
ASSAY DEVELOPMENT: GLOW AND NO GLOW
To find the best drug candidate, scientists need to design easy-to-perform, large-scale, fast, and accurate assays. Think automation. Think high throughput screening. Scientists often work with tests that produce a fluorescent signal or color change because color is easy to measure, relatively inexpensive to design, and safe. Depending on the assay, a color change may or may not indicate a drug candidate works.
Imagine “Enzyme Z” causes “Disease Z.” Its cure lies in shutting down, inhibiting “Enzyme Z.” Enzymes feature active sites, a kind of pocket that binds various small molecules. Researchers manipulate these small molecule inhibitors to light up by emitting a fluorescent signal if they bind (shut down) the enzyme.
Scientists use similar colorimetric tests for large molecule drugs such as antibodies. Let’s say that activated “Receptor X” turns on a particular gene that, in turn, causes cancer. Scientists can engineer cells so when Receptor X is activated, the cell produces a green fluorescence and when it is not activated no green appears. Researchers are hoping for “no glow” or in lab-speak, a “blank.” Blanks are the winners that go on to the next stage of drug development.
HIT TO LEAD
High throughput screening ideally results in several promising drug candidates or “hits.” To become “leads” that merit animal testing, hits must pass rigorous in vitro testing. On this leg of the drug discovery voyage, researchers ask three questions:
1. Is the hit safe?
2. Is the hit specific to the target?
3. Does the hit show promise to treat the disease?
If a potential lead is supposed to inhibit an enzyme it should act on that particular enzyme. A lead with effects that are too general may result in a drug with dangerous adverse reactions. Therefore, researchers aim to develop a drug that inhibits the target at a concentration low enough to avoid interfering with related enzymes. This approach provides a therapeutic window within which the drug is effective and safe. (Article continues below)
Do you seek a broad, intuitive understanding of the science involved in biopharma? Our 3-day BioImmersion: Biotech for the Non-Scientist course will give you the knowledge to hold your own in the biotech industry.
Can’t make the face-to-face course? Check out our Biology of Biotech online course:
LEAD TO CANDIDATE
Biopharma companies typically put lead compounds through several rounds of optimization before they can become drug candidates for preclinical testing. Lead optimization is the process by which a drug candidate is designed via iterative rounds of synthesis. For small molecule drugs, this tweaking may include creating derivatives of the lead. Often made using computer-aided design (CAD), derivatives can help ensure the lead fits well with its target. Researchers then test each for improved potency, fewer side effects, solubility (making sure that the drug stays liquid and won’t form clumps) and shelf life, otherwise known as stability.
Of course, optimization for large molecule drugs differs because biologics are genetically encoded. Researchers have developed techniques to create mutations in proteins at specific locations. Again, the goal is to see if changes produce a better drug—maybe even one up to Huey Lewis’s rigorous standards. If so, researchers have at long last an official drug candidate, one ready for the rigors of preclinical testing in animals.
Emily Burke, PhD has worked in biopharma for 20 years, gaining science writing experience at The Scripps Research Institute and Ionis Pharmaceuticals. As a Ph.D. molecular biologist, she is passionate about advancing the public’s understanding of science. In addition to being a self-proclaimed “science geek,” she is regularly asked to speak at international scientific meetings. When not teaching and writing the WEEKLY for Biotech Primer, Dr. Burke swims with her swim club and performs regularly on the improv circuit in San Diego.